Novartis will acquire Avidity Biosciences for approximately $12 billion
By Padmanabhan Ananthan and Angela Christy M. (Reuters) -Swiss drugmaker Novartis said on Sunday it has agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash, as the company seeks to bolster its portfolio of treatments for rare muscle disorders. Under the terms of the deal, Avidity shareholders will receive $72…